Skip to main content
S&P 5007,637.76+1.14%DOW51,778.04+0.61%NASDAQ26,418.30+1.69%BTC$76,416.00+0.10%ETH$2,442.29+0.95%GOLD$4,397.70-0.05%OIL$100.86-1.03%
Smart Investors Daily
CO

NASDAQ · COCP

Cocrystal Pharma, Inc.

Healthcare · Biotechnology

$1.14

Up+$0.00 (+0.00%)

Updated Sep 18, 2026, 2:03 AM

SID Score

5.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
10.97M
P/E ratio
-1.22
Dividend yield
0.00%
52-week range
$0.76 – $2.03
Volume
13.82K
Avg. volume
1.57M

Price performance

COCP price history

1M range · 20 trading sessions · Daily adjusted prices

COCP closed at $1.14 after 20 trading sessions, down 2.56% for the selected period.

Last close
$1.14
Period change
-2.56%
Period low
$1.10
Period high
$1.24
Daily close
View OHLC price history
COCP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 17, 2026$1.14$1.1503$1.121$1.1413.82K
Sep 16, 2026$1.13$1.1729$1.11$1.1446.85K
Sep 15, 2026$1.21$1.23$1.1206$1.1433.99K
Sep 14, 2026$1.27$1.27$1.17$1.1723.07K
Sep 11, 2026$1.26$1.285$1.215$1.2458.54K
Sep 10, 2026$1.26$1.2756$1.22$1.2353.6K
Sep 9, 2026$1.18$1.29$1.175$1.24111.35K
Sep 8, 2026$1.15$1.20$1.1238$1.1861.39K
Sep 4, 2026$1.12$1.14$1.10$1.1343.42K
Sep 3, 2026$1.16$1.16$1.12$1.1329.25K
Sep 2, 2026$1.15$1.17$1.11$1.1656.68K
Sep 1, 2026$1.17$1.17$1.10$1.1234.76K
Aug 31, 2026$1.10$1.16$1.10$1.1648.49K
Aug 28, 2026$1.18$1.18$1.10$1.1028.74K
Aug 27, 2026$1.10$1.17$1.10$1.1444.94K
Aug 26, 2026$1.13$1.17$1.115$1.1218.79K
Aug 25, 2026$1.11$1.18$1.10$1.1371.84K
Aug 24, 2026$1.19$1.19$1.10$1.1146.04K
Aug 21, 2026$1.19$1.21$1.10$1.1584.97K
Aug 20, 2026$1.1577$1.225$1.1304$1.17175.91K

Latest COCP news

The latest Smart Investors Daily articles mentioning COCP.

Stock researchCompany · Overview

COCP research

Overview

Company profile and research snapshot.

Company profile

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
COCP recent ratings
DateFirmRatingTarget
Jun 20, 2025HC Wainwright & Co.Buy—
Jan 22, 2025HC Wainwright & Co.Buy—
Aug 22, 2024HC Wainwright & Co.Buy—
May 14, 2024HC Wainwright & Co.Buy—
Apr 4, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

No serious adverse events reported to date Preliminary efficacy results expected in late 2026 or early 2027 MIAMI, Fla. And BOTHELL, Wash., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced that the last subject has been dosed in its Phase 1b norovirus challenge study (NCT07198139) evaluating CDI-988

Yahoo · Aug 31, 2026

Cocrystal Pharma: The Strategic Reset Investors May Be Missing

By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss […] The post Cocrystal Pharma: The Strategic Reset Investors May Be Missing appeared first on ExecEdge.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By